JP4406607B2 - ペプチド及びこれを含む医薬 - Google Patents

ペプチド及びこれを含む医薬 Download PDF

Info

Publication number
JP4406607B2
JP4406607B2 JP2004530567A JP2004530567A JP4406607B2 JP 4406607 B2 JP4406607 B2 JP 4406607B2 JP 2004530567 A JP2004530567 A JP 2004530567A JP 2004530567 A JP2004530567 A JP 2004530567A JP 4406607 B2 JP4406607 B2 JP 4406607B2
Authority
JP
Japan
Prior art keywords
gpc3
peptide
fmoc
hla
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2004530567A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2004018667A1 (ja
Inventor
泰治 西村
哲也 中面
祐輔 中村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of JPWO2004018667A1 publication Critical patent/JPWO2004018667A1/ja
Application granted granted Critical
Publication of JP4406607B2 publication Critical patent/JP4406607B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2004530567A 2002-08-26 2003-08-19 ペプチド及びこれを含む医薬 Expired - Lifetime JP4406607B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002245831 2002-08-26
JP2002245831 2002-08-26
PCT/JP2003/010459 WO2004018667A1 (ja) 2002-08-26 2003-08-19 ペプチド及びこれを含む医薬

Publications (2)

Publication Number Publication Date
JPWO2004018667A1 JPWO2004018667A1 (ja) 2005-12-08
JP4406607B2 true JP4406607B2 (ja) 2010-02-03

Family

ID=31944202

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004530567A Expired - Lifetime JP4406607B2 (ja) 2002-08-26 2003-08-19 ペプチド及びこれを含む医薬

Country Status (4)

Country Link
JP (1) JP4406607B2 (enExample)
AU (1) AU2003254950A1 (enExample)
TW (1) TW200413406A (enExample)
WO (1) WO2004018667A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016102272A1 (en) * 2014-12-23 2016-06-30 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
US11559573B2 (en) 2014-12-23 2023-01-24 Immatics Biotechnologies Gmbh Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cells
CN115960205A (zh) * 2019-12-13 2023-04-14 南京大户生物科技有限公司 原发性肝癌相关抗原的胸腺依赖性淋巴细胞抗原表位肽及其应用

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201043699A (en) 2002-03-25 2010-12-16 Takara Bio Inc Process for producing cytotoxic lymphocyte
EP1666589B1 (en) 2003-08-22 2010-02-17 Takara Bio Inc. Process for producing cytotoxic lymphocytes
US7691586B2 (en) 2004-04-28 2010-04-06 Perseus Proteomics Inc. Method for predicting and judging the recurrence of liver cancer after treating liver cancer
AU2005256113B2 (en) 2004-07-09 2011-02-10 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
KR101300546B1 (ko) 2004-08-24 2013-09-02 추가이 세이야쿠 가부시키가이샤 항 글리피칸 3 항체를 이용한 어쥬번트 요법
KR101296931B1 (ko) 2004-10-26 2013-08-14 추가이 세이야쿠 가부시키가이샤 변형된 당쇄를 갖는 항-글리피칸 3 항체
EP2289532A1 (en) 2005-02-28 2011-03-02 Oncotherapy Science, Inc. Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
JP5095603B2 (ja) 2005-07-27 2012-12-12 オンコセラピー・サイエンス株式会社 結腸癌関連遺伝子ｔｏｍ３４
JP5299942B2 (ja) * 2005-08-09 2013-09-25 オンコセラピー・サイエンス株式会社 ＨＬＡ−Ａ２陽性者用ｇｌｙｐｉｃａｎ−３（ＧＰＣ３）由来癌拒絶抗原ペプチド及びこれを含む医薬
WO2007020880A1 (ja) 2005-08-17 2007-02-22 Takara Bio Inc. リンパ球の製造方法
WO2007040105A1 (ja) * 2005-09-30 2007-04-12 Takara Bio Inc. Ｔ細胞集団の製造方法
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
WO2008017517A1 (en) 2006-08-11 2008-02-14 Life Sciences Research Partners Vzw Immunogenic peptides and their use in immune disorders
PE20130588A1 (es) 2007-02-02 2013-05-21 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
AU2008304111B2 (en) 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
US8796206B2 (en) 2007-11-15 2014-08-05 Amgen Inc. Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
TW200932260A (en) * 2007-11-28 2009-08-01 Oncotherapy Science Inc STAT3 epitope peptides
EP2803675A3 (en) 2008-01-25 2014-12-24 Amgen, Inc Ferroportin antibodies and methods of use
WO2009101205A2 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Immunogenic control of tumours and tumour cells
WO2009101204A2 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Elimination of immune responses to viral vectors
US20120009678A1 (en) 2008-02-14 2012-01-12 Jean-Marie Saint-Remy Immunotherapy targeting intracellular pathogens
EP2245059B1 (en) 2008-02-14 2017-09-20 Life Sciences Research Partners VZW Cd4+ t-cells with cytolytic properties
WO2009139822A1 (en) 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
CA2742871C (en) 2008-11-13 2018-10-23 Herb Lin Methods and compositions for regulating iron homeostasis by modulation of bmp-6
US9662271B2 (en) 2009-10-23 2017-05-30 Amgen Inc. Vial adapter and system
ES2545411T5 (es) 2010-06-07 2024-04-05 Amgen Inc Dispositivo de administración de fármaco
BR112013005448A2 (pt) * 2010-09-07 2019-09-24 Oncotherapy Science Inc peptídeos de ttll4 e vacinas contendo os mesmos.
US20130287805A1 (en) * 2010-10-21 2013-10-31 Yusuke Nakamura C18orf54 peptides and vaccines including the same
TW201216982A (en) * 2010-10-21 2012-05-01 Oncotherapy Science Inc WDHD1 peptides and vaccines including the same
US10023847B2 (en) 2010-11-25 2018-07-17 Imnate Sarl Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
TWI618541B (zh) 2010-12-02 2018-03-21 腫瘤療法 科學股份有限公司 Ｔｏｍｍ３４胜肽與含此胜肽之疫苗
WO2012135315A1 (en) 2011-03-31 2012-10-04 Amgen Inc. Vial adapter and system
LT2699293T (lt) 2011-04-20 2019-04-25 Amgen Inc. Automatinio purškimo prietaisas
EP3045187B1 (en) 2011-10-14 2019-04-10 Amgen Inc. Injector and method of assembly
GB201201511D0 (en) 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
KR20140138900A (ko) 2012-03-09 2014-12-04 온코세라피 사이언스 가부시키가이샤 펩티드를 포함한 의약 조성물
JP2015535464A (ja) 2012-11-21 2015-12-14 アムジエン・インコーポレーテツド 薬剤送達装置
CN103961697A (zh) * 2013-02-05 2014-08-06 日东电工株式会社 粘膜给予用疫苗组合物
CA2840937A1 (en) * 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for transdermal administration
TWI592183B (zh) 2013-03-15 2017-07-21 安美基公司 本體輪廓可調適之自動注射器裝置
US10492990B2 (en) 2013-03-15 2019-12-03 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
US10092703B2 (en) 2013-03-15 2018-10-09 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
CA2904357C (en) 2013-03-15 2020-09-22 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
ES2853748T3 (es) 2013-03-22 2021-09-17 Amgen Inc Inyector y método de montaje
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
MX2016005315A (es) 2013-10-24 2016-08-11 Amgen Inc Sistema de administracion de farmacos con control sensible a la temperatura.
EP3060275B1 (en) 2013-10-24 2019-07-03 Amgen Inc. Injector and method of assembly
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
SG11201609219QA (en) 2014-05-07 2016-12-29 Amgen Inc Autoinjector with shock reducing elements
US20170103186A1 (en) 2014-06-03 2017-04-13 Amgen Inc. Systems and methods for supporting patient use of a drug delivery device
CA2961917A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016056596A1 (ja) 2014-10-07 2016-04-14 日本電気株式会社 Ｈｓｐ７０由来のペプチド、これを用いた癌の治療又は予防のための医薬組成物、免疫誘導剤、及び抗原提示細胞の製造方法
ES3056224T3 (en) 2014-10-14 2026-02-19 Amgen Inc Drug injection device with visual and audible indicators
TW201636358A (zh) * 2014-12-09 2016-10-16 腫瘤療法 科學股份有限公司 對於ｔｈ１細胞之ｇｐｃ３抗原決定位胜肽及含此之疫苗
US10799630B2 (en) 2014-12-19 2020-10-13 Amgen Inc. Drug delivery device with proximity sensor
EP3689394A1 (en) 2014-12-19 2020-08-05 Amgen Inc. Drug delivery device with live button or user interface field
US10583245B2 (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
ES2905870T3 (es) 2015-02-27 2022-04-12 Amgen Inc Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja
US10526388B2 (en) * 2015-03-09 2020-01-07 Cytlimic Inc. Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells
AU2016244570B2 (en) 2015-04-07 2020-08-27 Nec Corporation Medicine
US10729791B2 (en) 2015-05-18 2020-08-04 Imcyse Sa Animal models for evaluating pharmaceutical compounds
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
EP3352782B1 (en) 2015-09-25 2021-03-31 ImCyse SA Improved methods and compounds for eliminating immune responses to therapeutic agents
JP7082568B2 (ja) 2015-12-09 2022-06-08 アムジエン・インコーポレーテツド 信号伝達キャップ付き自動注射器
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
WO2017160799A1 (en) 2016-03-15 2017-09-21 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
WO2017182528A1 (en) 2016-04-19 2017-10-26 Imcyse Sa Novel immunogenic cd1d binding peptides
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
MX2018013616A (es) 2016-05-13 2019-02-21 Amgen Inc Montaje de cubierta protectora de vial.
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
ES3066292T3 (en) 2016-06-03 2026-05-12 Amgen Inc Impact testing apparatuses and methods for drug delivery devices
EP3478342B1 (en) 2016-07-01 2025-03-12 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
US11291718B2 (en) 2016-10-11 2022-04-05 Cytlimic Inc. Method for treating cancer by administering a toll-like receptor agonist and LAG-3 IgG fusion protein
EP3532127B1 (en) 2016-10-25 2026-04-08 Amgen Inc. On-body injector
JP2018093823A (ja) 2016-12-15 2018-06-21 Ｈｅａｒｔｓｅｅｄ株式会社 未分化幹細胞除去剤及び未分化幹細胞除去方法
WO2018136398A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
US11603519B2 (en) 2017-02-06 2023-03-14 National Cancer Center Japan T-cell receptor
MX2019009755A (es) 2017-02-17 2019-10-07 Amgen Inc Mecanismo de insercion para dispositivo de suministro de farmacos.
AU2018220538B2 (en) 2017-02-17 2023-12-14 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
WO2018165143A1 (en) 2017-03-06 2018-09-13 Amgen Inc. Drug delivery device with activation prevention feature
KR102627069B1 (ko) 2017-03-07 2024-01-18 암겐 인코포레이티드 과압에 의한 바늘 삽입
SG11201908062QA (en) 2017-03-09 2019-09-27 Amgen Inc Insertion mechanism for drug delivery device
WO2018172219A1 (en) 2017-03-20 2018-09-27 F. Hoffmann-La Roche Ag Method for in vitro glycoengineering of an erythropoiesis stimulating protein
MX2019011416A (es) 2017-03-28 2019-11-01 Amgen Inc Sistema y metodo para conjunto de jeringa y vastago de embolo.
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
CA3066399A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
MA49447A (fr) 2017-06-22 2020-04-29 Amgen Inc Réduction des impacts/chocs d'activation d'un dispositif
JP7475860B2 (ja) 2017-06-23 2024-04-30 アムジエン・インコーポレーテツド スイッチアセンブリにより起動されるキャップを含む電子薬物送達デバイス
JP7408398B2 (ja) 2017-07-14 2024-01-05 アムジエン・インコーポレーテツド 二重ねじりばねシステムを有する針挿入後退システム
JP7649105B2 (ja) 2017-07-21 2025-03-19 アムジエン・インコーポレーテツド 薬物容器のためのガス透過性シーリング部材及び組立方法
WO2019022951A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSEMBLY METHOD THEREOF
EP3658206A1 (en) 2017-07-25 2020-06-03 Amgen Inc. Drug delivery device with container access system and related method of assembly
US12318593B2 (en) 2017-08-09 2025-06-03 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
EP3668567B1 (en) 2017-08-18 2026-02-18 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
EP3691717B1 (en) 2017-10-04 2023-02-08 Amgen Inc. Flow adapter for drug delivery device
EP4257164A3 (en) 2017-10-06 2024-01-17 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
MA50348A (fr) 2017-10-09 2020-08-19 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
ES3069718T3 (en) 2017-11-03 2026-06-10 Amgen Inc System and approaches for sterilizing a drug delivery device
MA50569A (fr) 2017-11-06 2020-09-16 Amgen Inc Ensembles de remplissage-finition et procédés associés
CA3079197A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
IL319987A (en) 2017-11-10 2025-06-01 Amgen Inc Plungers for drug delivery devices
JP7747438B2 (ja) 2017-11-16 2025-10-01 アムジエン・インコーポレーテツド 失速及び終点検出を有するオートインジェクタ
AU2018368340B2 (en) 2017-11-16 2024-03-07 Amgen Inc. Door latch mechanism for drug delivery device
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
US12303677B2 (en) 2018-07-24 2025-05-20 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
CN112469454B (zh) 2018-07-24 2024-01-26 安进公司 用于施用药物的输送装置
CA3103682A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
MA53320A (fr) 2018-07-31 2021-11-03 Amgen Inc Ensemble de trajet de fluide pour dispositif d'administration de médicament
CA3106452A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
US12042642B2 (en) 2018-09-28 2024-07-23 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
WO2020072577A1 (en) 2018-10-02 2020-04-09 Amgen Inc. Injection systems for drug delivery with internal force transmission
JP7547325B2 (ja) 2018-10-05 2024-09-09 アムジエン・インコーポレーテツド 投薬量インジケータを有する薬物送達デバイス
MA53913A (fr) 2018-10-15 2022-01-19 Amgen Inc Procédé d'assemblage de plate-forme pour dispositif d'administration de médicament
JP7719714B2 (ja) 2018-10-15 2025-08-06 アムジエン・インコーポレーテツド ダンピング機構を有する薬物送達装置
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
WO2020091956A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
MA54057A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
EP3958934B1 (en) 2019-04-24 2025-04-09 Amgen Inc. Syringe sterilization verification assemblies and methods
US20220273887A1 (en) 2019-08-23 2022-09-01 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
BR112023024278A2 (pt) 2021-05-21 2024-01-30 Amgen Inc Método de otimizar uma receita de enchimento para um recipiente de fármacos
JP2025536587A (ja) 2022-11-02 2025-11-07 エフ． ホフマン－ラ ロシュ アーゲー 糖タンパク質組成物を生産するための方法
KR20260020412A (ko) 2023-06-16 2026-02-11 살루브리스 (청두) 바이오테크 코., 리미티드 항-gpc3 항체 또는 항원 결합 단편 및 이의 용도
WO2026030152A1 (en) 2024-07-29 2026-02-05 Amgen Inc. System and method for assessing transferability of a fill recipe

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11679147B2 (en) 2014-12-23 2023-06-20 Immatics Biotechnologies Gmbh Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cells
US11779638B2 (en) 2014-12-23 2023-10-10 Immatics Biotechnologies Gmbh Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cells
EP3545965A3 (en) * 2014-12-23 2019-12-25 immatics Biotechnologies GmbH Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
US11406693B2 (en) 2014-12-23 2022-08-09 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
US11559573B2 (en) 2014-12-23 2023-01-24 Immatics Biotechnologies Gmbh Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cells
US11576956B2 (en) 2014-12-23 2023-02-14 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
JP2018509135A (ja) * 2014-12-23 2018-04-05 イマティクス バイオテクノロジーズ ゲーエムベーハー 肝細胞がん（ｈｃｃ）およびその他のがんに対する免疫療法で使用するための新規ペプチドおよびペプチド組み合わせ
EP4461371A3 (en) * 2014-12-23 2025-02-26 immatics biotechnologies GmbH Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
WO2016102272A1 (en) * 2014-12-23 2016-06-30 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
US11672848B2 (en) 2014-12-23 2023-06-13 Immatics Biotechnologies Gmbh Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cells
US11786583B2 (en) 2014-12-23 2023-10-17 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against Hepatocellular carcinoma (HCC) and other cancers
US12070491B2 (en) 2014-12-23 2024-08-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
US12076380B2 (en) 2014-12-23 2024-09-03 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
US12097248B2 (en) 2014-12-23 2024-09-24 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
US12121572B2 (en) 2014-12-23 2024-10-22 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
CN115960205A (zh) * 2019-12-13 2023-04-14 南京大户生物科技有限公司 原发性肝癌相关抗原的胸腺依赖性淋巴细胞抗原表位肽及其应用

Also Published As

Publication number Publication date
TWI333958B (enExample) 2010-12-01
WO2004018667A1 (ja) 2004-03-04
JPWO2004018667A1 (ja) 2005-12-08
AU2003254950A1 (en) 2004-03-11
TW200413406A (en) 2004-08-01

Similar Documents

Publication Publication Date Title
JPWO2004018667A1 (ja) ペプチド及びこれを含む医薬
JP7589193B2 (ja) 免疫原性ｗｔ－１ペプチドおよびその使用法
JP6490581B2 (ja) 修飾型自己エピトープに対する抗腫瘍免疫応答
RU2721574C2 (ru) Вакцинная композиция против злокачественной опухоли
JP5909767B2 (ja) Ｆｏｘｍ１ペプチドおよびこれを含む薬剤
US9404925B2 (en) Cancer antigen and use thereof
JP2007516966A (ja) 合成ｈｌａ結合ペプチド類似体及びその使用方法
JP5299942B2 (ja) ＨＬＡ−Ａ２陽性者用ｇｌｙｐｉｃａｎ−３（ＧＰＣ３）由来癌拒絶抗原ペプチド及びこれを含む医薬
US8507273B2 (en) Gene encoding a multidrug resistance human P-glycoprotein homologue on chromosome 7p15-21 and uses thereof
TW201200525A (en) MYBL2 peptides and vaccines containing the same
WO2024262558A1 (ja) ヒト内在性レトロウイルス遺伝子によってコードされる腫瘍抗原ペプチド
HK40100878A (en) Immunogenic wt-1 peptides and methods of use thereof
CA2874515C (en) Anti-tumour immune responses to modified self-epitopes
CN108250286A (zh) 源自于pasd1的肿瘤抗原短肽
HK1140774B (en) Foxm1 peptide and medicinal agent comprising the same
HK1244819B (en) Foxm1 peptide and medicinal agent comprising the same

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060720

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20070816

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080529

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090810

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091027

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20091109

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121113

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4406607

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121113

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121113

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121113

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121113

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131113

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

EXPY Cancellation because of completion of term